# Progress Note 04 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Marie Curie (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET013-SYN-TD
- Date: 1934-06-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Adaeze Nwosu, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-week review on immunosuppressive therapy, one week after laser capsulotomy. **S**

## History of present illness

Madame Curie returns six weeks after starting immunosuppressive therapy. She has had no fever, infection, or bleeding, and the bruising has lessened. She has a little more energy in the afternoons. She takes cyclosporine, eltrombopag, and acyclovir as prescribed. Ophthalmology confirmed posterior capsule opacification in the right eye two weeks ago and performed a YAG laser capsulotomy one week ago. She now reads standard print without glare, with no eye pain, redness, new floaters, flashes, or shadow in her vision. She is frustrated at being away from her laboratory. **S**

| Element | Detail |
|---|---|
| Infection and bleeding | None; fewer bruises |
| Energy | A little better in the afternoons |
| Adherence | Cyclosporine, eltrombopag, and acyclovir as prescribed |
| Eye | Laser capsulotomy one week ago; reading standard print without glare |
| After laser | No pain, redness, new floaters, flashes, or shadow |
| Mood | Frustrated at time away from the laboratory |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Fatigue improving; no fever |
| Hematologic | Negative | No new bruising or bleeding |
| Eyes | Negative | Clear reading vision on the right; no pain, floaters, flashes, or shadow |
| Skin | Negative | No rash |
| Psychiatric | Positive | Frustrated at time away from work; sleeping and eating well; PHQ-2 score 2 |

5 systems reviewed. **S**

## Current medications

- Cyclosporine (modified) 100 mg oral capsule, one capsule twice daily, dose adjusted to trough levels by hematology **S**
- Eltrombopag 75 mg oral tablet, two tablets (150 mg) once daily on an empty stomach **S**
- Acyclovir 400 mg oral tablet, one tablet twice daily during immunosuppression **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/78 mmHg; pulse 86 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 52 kg; BMI 21.1 kg/m². All vital signs are synthetic.

Hemoglobin: 8.9 g/dL (low); White blood cell count: 2.4 10*3/uL (low); Absolute neutrophil count: 0.8 10*3/uL (low); Platelet count: 34 10*3/uL (low); MCV: 101 fL (high); Absolute reticulocyte count: 31 10*3/uL; ALT: 31 U/L; Sodium: 138 mmol/L; Potassium: 4.9 mmol/L; Creatinine: 1.02 mg/dL; eGFR: 61 mL/min/1.73 m²; Glucose: 98 mg/dL; PHQ-2: 2. All results are synthetic.

## Change since baseline

- Hemoglobin: 7.2 g/dL (low) at baseline, 8.9 g/dL (low) at this visit **S**
- White blood cell count: 1.9 10*3/uL (low) at baseline, 2.4 10*3/uL (low) at this visit **S**
- Absolute neutrophil count: 0.4 10*3/uL (low) at baseline, 0.8 10*3/uL (low) at this visit **S**
- Platelet count: 18 10*3/uL (low) at baseline, 34 10*3/uL (low) at this visit **S**
- MCV: 104 fL (high) at baseline, 101 fL (high) at this visit **S**
- Absolute reticulocyte count: 14 10*3/uL (low) at baseline, 31 10*3/uL at this visit **S**
- Sodium: 139 mmol/L at baseline, 138 mmol/L at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 4.9 mmol/L at this visit **S**
- Creatinine: 0.78 mg/dL at baseline, 1.02 mg/dL at this visit **S**
- eGFR: 84 mL/min/1.73 m² at baseline, 61 mL/min/1.73 m² at this visit **S**
- Glucose: 94 mg/dL at baseline, 98 mg/dL at this visit **S**
- PHQ-2: 1 at baseline, 2 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Less pale; alert and engaged |
| Mouth | No ulcers, thrush, or gum swelling |
| Skin | Fading bruises on the shins; no petechiae |
| Heart | Regular rhythm, pulse 86 |
| Eyes | Right red reflex now clear; both eyes white and quiet |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Severe aplastic anemia, early response to immunosuppressive therapy** (D61.2). Early rise in counts without transfusion since the first visit: neutrophils 0.8 (from 0.4), platelets 34 (from 18), reticulocytes 31 thousand per microliter, hemoglobin 8.9 g/dL. No infection or bleeding. Creatinine 1.02 mg/dL is about 30 percent above the pre-treatment 0.78 (eGFR 61) and potassium is 4.9 on cyclosporine; ALT 31. **S**
   - Continue cyclosporine at the current dose until hematology reviews it, with eltrombopag and acyclovir.
   - Hematology contacted today to review the cyclosporine dose against a trough level, given the creatinine rise.
   - Repeat creatinine and potassium within a week with the weekly counts.
   - Formal response assessment at three months.
2. **Posterior capsule opacification, right eye, treated** (H26.491). Reading without glare one week after YAG laser capsulotomy; reading goal met. **S**
   - Call the same day for new floaters, flashes, a shadow, pain, or loss of vision.
   - Comprehensive eye examination every one to two years.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | CBC with differential and reticulocyte count | Weekly during the first months of treatment | Completed today | Hemoglobin 8.9 g/dL, white cells 2.4, neutrophils 0.8, platelets 34, reticulocytes 31 thousand per microliter |
| Laboratory | Weekly blood counts between visits | Weekly during the first months of treatment | Deferred | Again no counts are in this record between visits, a second deviation from the protocol. Counts are rising with no bleeding or infection, so no harm resulted. Corrective action: weekly counts confirmed with the hematology day unit |
| Laboratory | Creatinine, eGFR, potassium, and ALT on cyclosporine and eltrombopag | Every two weeks during the first months of treatment | Completed today | Three weeks after the last check, a week late. Creatinine 1.02 mg/dL (about 30 percent above baseline), eGFR 61, potassium 4.9, ALT 31 |
| Laboratory | Cyclosporine trough level | Regularly from the first weeks of treatment, to guide the dose | Deferred | Still no trough level in this record, a second deviation from the protocol. The creatinine rise now warrants a dose review. Corrective action: hematology contacted today for a trough and dose review |
| Laboratory | Viral serology before immunosuppression (hepatitis B, hepatitis C, HIV, CMV, EBV) | At diagnosis, before immunosuppression | Deferred | Still not in this record. ALT remains normal. Corrective action: hematology asked again today |
| Examination | Blood pressure and weight on cyclosporine | Every visit | Completed today | 128/78 mmHg; weight 52 kg |
| Medication safety | Antiviral prophylaxis during immunosuppression | Throughout immunosuppression | Completed today | Taking acyclovir twice daily |
| Medication safety | Antibacterial and antifungal prophylaxis while severely neutropenic | While neutrophils are below 0.5 thousand per microliter, by local policy | Not indicated | Neutrophils 0.8, above the severe-neutropenia range |
| Self-management | Same-day assessment for a temperature of 38 °C or higher; bleeding precautions; no aspirin or NSAIDs | Every visit | Completed today | No fever; plan reviewed |
| Survey | Symptom assessment (fatigue, breathlessness, exercise tolerance) | Every visit during active treatment | Completed today | Energy a little better in the afternoons |
| Examination | Comprehensive dilated eye examination | Every 1 to 2 years at 65 or older | Up to date | Done by ophthalmology two weeks ago: 20/60 right and 20/30 left before laser, normal pressure, no retinal hemorrhages |
| Examination | Pressure check after laser capsulotomy | After the laser | Deferred | No post-laser pressure reading is in this record. No pain, halos, or loss of vision, and reading has improved, so no harm is apparent. Corrective action: request the laser-day note from ophthalmology |
| Self-management | Warning signs of retinal detachment after capsulotomy | After the laser | Completed today | Reviewed: new floaters, flashes, or a shadow need a same-day call |
| Survey | Functional vision assessment (reading, driving, work) | After treatment | Completed today | Reading standard print without glare |
| Survey | Depression screen (PHQ-2) | Periodically during serious illness | Completed today | Score 2, negative; frustration at time away from work |
| Survey | Response assessment (blood counts off transfusion) | At three and six months | Due | At three months |

## Goal progress

- Hematology evaluation with bone marrow biopsy within one week of the pancytopenia result. Outcome by 1934-05-18: Seen and biopsied seven days after the first visit. **S**
- No serious infection or bleeding during the first months of treatment. Outcome by 1934-06-29: No infection or bleeding through the sixth week of therapy. **S**
- Early rise in neutrophil and platelet counts by the six-week visit. Outcome by 1934-06-29: Neutrophils rose from 0.4 to 0.8 and platelets from 18 to 34 thousand per microliter; formal response is judged at three to six months. **S**
- Read standard print comfortably with the right eye after capsulotomy. Outcome by 1934-06-29: Reading without glare one week after laser capsulotomy. **S**

## Guideline basis

- Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline (2024), British Society for Haematology (British Journal of Haematology)
- Cataract in the Adult Eye Preferred Practice Pattern (2021), American Academy of Ophthalmology
- CMID: Clinical Monitoring Intelligence Database, anemia and cataract monographs (2026), Aether Forge

## Follow-up

- Weekly blood counts with creatinine and potassium this week. Primary care review in three weeks. Formal response assessment at three months. **S**

